Chargement en cours...
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
PURPOSE: Ovarian cancer is the most lethal gynaecological malignancy. Despite the introduction of bevacizumab, standard chemotherapy has remained largely unchanged and the vast majority of patients will relapse within the first two years of diagnosis. However, results from recent clinical trials dem...
Enregistré dans:
| Publié dans: | Arch Gynecol Obstet |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Berlin Heidelberg
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7524817/ https://ncbi.nlm.nih.gov/pubmed/32833070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00404-020-05677-1 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|